http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006123226-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc4241ff49f7d0f61e8f976a69931244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7f4a3644346774daa0da1c9fde8fce9
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
filingDate 2006-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4de3c9a4a563f6374871eb7b12229c37
publicationDate 2007-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2006123226-A3
titleOfInvention An inhibitor of mtor for inhibiting the formation of scar tissue
abstract The invention describes the use of an inhibitor of the mammalian Target of Rapamycin (mTOR), such as sirolimus or everolimus, to effect a clinical response on an insult or wound. The compound can be administered in any suitable local or topical delivery form, such as by local injection; local delivery systems, for example impregnated implants and slow release devices; forms of dressings, impregnated suturing material; impregnated mesh, sheets, membranes, prosthetics; gels containing the compound; and so forth. Typical applications where it would be useful to prevent scarring by inhibiting the mTOR according to the invention are: cosmetic surgery; scar revision surgery, including excision of scars and contracture release; tendon repair; nerve repair; and fibrotic or inflammatory conditions, such as de Quervain's disease, Peyronie's disease, plantar fasciitis, Dupuytren's disease, finger triggering, forms of synovitis, such as rheumatoid arthritis, after laparotomy to prevent adhesions, after brain surgery to prevent gliosis, and microsurgery, such as microvascular surgery and fallopian tube surgery.
priorityDate 2005-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005084514-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004087613-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004110347-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439492
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57312764
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176872
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46835353
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396389
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID442514
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID244346398
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136314073
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135985134
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395632
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4271
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136305982
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395633
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136045608
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136015015
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57317596
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID478951
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129178479

Total number of triples: 37.